Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/38803
Full metadata record
DC FieldValueLanguage
dc.contributor.authorO'Neill, S.-
dc.contributor.authorMacLennan, A.-
dc.contributor.authorDiamond, T.-
dc.contributor.authorEbeling, P.-
dc.contributor.authorFindlay, D.-
dc.contributor.authorFlicker, L.-
dc.contributor.authorMarkwell, A.-
dc.contributor.authorNowson, C.-
dc.contributor.authorPocock, N.-
dc.contributor.authorSambrook, P.-
dc.contributor.authorFiatarone-Singh, M.-
dc.date.issued2004-
dc.identifier.citationAustralian Family Physician, 2004; 33(11):910-919-
dc.identifier.issn0300-8495-
dc.identifier.urihttp://hdl.handle.net/2440/38803-
dc.descriptionCopyright © 2004 Royal Australian College of General Practitioners Copyright to Australian Family Physician. Reproduced with permission. Permission to reproduce must be sought from the publisher, The Royal Australian College of General Practitioners.-
dc.description.abstractBackground: Since the last series of guidelines on the management of osteoporosis from Osteoporosis Australia was published in Australian Family Physician (October 2002), there have been further advances in our understanding of the treatment involved in both the prevention of bone loss and the management of established osteoporosis. Objective: This article provides updated guidelines for the management of postmenopausal osteoporosis to assist general practitioners identify those women at risk, and reviews current treatment strategies. DISCUSSION: Osteoporosis and its associated problems are major health concerns in Australia, especially with an aging population. While important principles of management are still considered to be maximising peak bone mass and preventing postmenopausal bone loss, new clinical trial data about drugs such as the bisphosphonates, raloxifene and oestrogen have recently become available and the relative role of various agents is gradually becoming clearer. The use of long term hormone therapy has mixed risks and benefits that requires individual patient counselling.-
dc.description.statementofresponsibilityO'Neill S; MacLennan A; Bass S; Diamond T; Ebeling P; Findlay D; Flicker L; Markwell A; Nowson C; Pocock N; Sambrook P; Singh MF-
dc.language.isoen-
dc.publisherRoyal Australian College of General Practitioners-
dc.source.urihttp://www.racgp.org.au/afp/200411/14287-
dc.subjectOsteoporosis Australia Medical Scientific Committee-
dc.subjectHumans-
dc.subjectBone Diseases, Metabolic-
dc.subjectOsteoporosis, Postmenopausal-
dc.subjectCalcium-
dc.subjectOrganometallic Compounds-
dc.subjectDiphosphonates-
dc.subjectThiophenes-
dc.subjectBenzothiadiazines-
dc.subjectSelective Estrogen Receptor Modulators-
dc.subjectParathyroid Hormone-
dc.subjectVitamin D-
dc.subjectAntihypertensive Agents-
dc.subjectDiuretics-
dc.subjectAbsorptiometry, Photon-
dc.subjectDrug Therapy, Combination-
dc.subjectEstrogen Replacement Therapy-
dc.subjectRisk Factors-
dc.subjectFamily Practice-
dc.subjectAged-
dc.subjectMiddle Aged-
dc.subjectFemale-
dc.subjectSodium Chloride Symporter Inhibitors-
dc.subjectFractures, Bone-
dc.subjectBiomarkers-
dc.titleGuidelines for the management of postmenopausal osteoporosis for GPs-
dc.typeJournal article-
pubs.publication-statusPublished-
Appears in Collections:Aurora harvest
Orthopaedics and Trauma publications

Files in This Item:
File Description SizeFormat 
hdl_38803.pdf164 kBPublisher's PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.